Identifying a targeted population at high risk for infections after liver transplantation in the MELD era

Clinical Transplantation

Volumn 25, Issue 3, 2011, Pages 420-425

  Sun, Hsin Yun ^a,b   Cacciarelli, Thomas V ^a,c   Singh, Nina ^a,c  

^a Veteran Affairs Pittsburgh Health Care System   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

D model for end stage liver disease; Liver transplant; Model for end stage liver disease; Mortality; Post transplant dialysis; Post transplant infection

Indexed keywords

ADULT; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; DIALYSIS; FEMALE; GRAFT RECIPIENT; HIGH RISK POPULATION; HUMAN; LIVER GRAFT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REOPERATION; RETRANSPLANTATION; RISK FACTOR; SCORING SYSTEM;

END STAGE LIVER DISEASE; FEMALE; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; IMMUNOCOMPROMISED HOST; INFECTION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 79551492924     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01262.x     Document Type: Article

References (31)

1. Singh N. Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients. Lancet Infect Dis 2003: 3: 156.
2. Singh N, Wagener MM, Obman A, Cacciarelli TV, De Vera ME, Gayowski T. Bacteremias in liver transplant recipients: shift toward gram-negative bacteria as predominant pathogens. Liver Transpl 2004: 10: 844.
3. Singh N, Avery RK, Munoz P et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003: 36: 46.
4. Singh N, Wagener MM, Marino IR, Gayowski T. Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation 2002: 73: 63.
5. Freeman RB Jr, Wiesner RH, Harper A et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002: 8: 851.
6. Freeman RB, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R. Results of the first year of the new liver allocation plan. Liver Transpl 2004: 10: 7.
7. Berg CL, Steffick DE, Edwards EB et al. Liver and intestine transplantation in the United States 1998-2007. Am J Transplant 2009: 9: 907.
8. Dellon ES, Galanko JA, Medapalli RK, Russo MW. Impact of dialysis and older age on survival after liver transplantation. Am J Transplant 2006: 6: 2183.
9. Kanwal F, Dulai GS, Spiegel BM, Yee HF, Gralnek IM. A comparison of liver transplantation outcomes in the pre- vs. post-MELD eras. Aliment Pharmacol Ther 2005: 21: 169.
10. Gonwa TA, Mcbride MA, Anderson K, Mai ML, Wadei H, Ahsan N. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us? Am J Transplant 2006: 6: 2651.
11. Halldorson JB, Bakthavatsalam R, Fix O, Reyes JD, Perkins JD. D-MELD, a simple predictor of post liver transplant mortality for optimization of donor/recipient matching. Am J Transplant 2009: 9: 318.
12. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988: 16: 128.
13. Singh N, Gayowski T, Rihs JD, Wagener MM, Marino IR. Evolving trends in multiple-antibiotic-resistant bacteria in liver transplant recipients: a longitudinal study of antimicrobial susceptibility patterns. Liver Transpl 2001: 7: 22.
14. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 2001: 71: 910.
15. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005: 79: 85.
16. Singh N, Wannstedt C, Keyes L et al. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalo-virus-seropositive donor allografts. Liver Transpl 2008: 14: 240.
17. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999: 131: 729.
18. Kusne S, Dummer JS, Singh N et al. Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) 1988: 67: 132.
19. Paterson DL, Singh N, Panebianco A et al. Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. Transplantation 1998: 66: 593.
20. Singh N, Gayowski T, Wagener MM, Marino IR. Predictors and outcome of early- versus late-onset major bacterial infections in liver transplant recipients receiving tacrolimus (FK506) as primary immunosuppression. Eur J Clin Microbiol Infect Dis 1997: 16: 821.
21. Gayowski T, Marino IR, Singh N et al. Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. Transplantation 1998: 65: 499.
22. Collins LA, Samore MH, Roberts MS et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994: 170: 644.
23. Husain S, Tollemar J, Dominguez EA et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003: 75: 2023.
24. Fortun J, Martin-Davila P, Moreno S et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002: 8: 1065.
25. Bellier C, Bert F, Durand F et al. Risk factors for Enterobacteriaceae bacteremia after liver transplantation. Transpl Int 2008: 21: 755.
26. Freeman RB Jr. Model for end-stage liver disease (MELD) for liver allocation: a 5-year score card. Hepatology 2008: 47: 1052.
27. Rana A, Hardy MA, Halazun KJ et al. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant 2008: 8: 2537.
28. Desai NM, Mange KC, Crawford MD et al. Predicting outcome after liver transplantation: utility of the model for end-stage liver disease and a newly derived discrimination function. Transplantation 2004: 77: 99.
29. Zamboni F, Franchello A, David E et al. Effect of macrovescicular steatosis and other donor and recipient characteristics on the outcome of liver transplantation. Clin Transplant 2001: 15: 53.
30. Schaubel DE, Sima CS, Goodrich NP, Feng S, Merion RM. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008: 8: 419.
31. Feng S, Goodrich NP, Bragg-Gresham JL et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006: 6: 783.